Scancell and Neuphoria Announce Merger and Planned Nasdaq Listing

Key Facts

In a move reflecting strategic consolidation within the biotech sector, Scancell Holdings and Neuphoria Therapeutics have announced a definitive all-share merger agreement. Scancell will acquire Neuphoria to combine their respective resources and pipeline assets. The merger is designed to enhance investor reach and liquidity by establishing a primary listing on the Nasdaq exchange for the combined entity.

This merger underscores the ongoing M&A momentum in the healthcare industry as the new entity prepares to trade under the symbol SCLT. According to reports, the combination aims to leverage the strengths of both companies' research portfolios. The transition to a Nasdaq listing is a pivotal step intended to provide the merged business with superior access to capital markets compared to individual operations.

Completion of the deal remains subject to shareholder approvals and regulatory conditions, including SEC review and the effectiveness of registration statements. While current instrument prices are unavailable as of July 23, 2026, the upcoming Nasdaq listing serves as the primary catalyst for investors. Market participants will also be watching broader US economic indicators, such as consumer sentiment and inflation data, to gauge the appetite for high-growth biotech stocks.